Anacor Pharmaceuticals Earnings: Everything You Must Know Now

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Anacor Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.42 in the quarter versus EPS of $-0.48 in the year-earlier quarter.

Revenue: Decreased 29.75% to $1.7 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Anacor Pharmaceuticals, Inc. reported adjusted EPS loss of $0.42 per share. By that measure, the company missed the mean analyst estimate of $-0.39. It missed the average revenue estimate of $2.57 million.

Quoting Management: “It was an eventful first quarter. We reported positive data from our two Phase 3 trials of tavaborole in onychomycosis, and we are on track to file our NDA around the middle of this year. In addition, we reported successful results from our third Phase 2 trial of AN2728 in atopic dermatitis, which informed the most efficacious dosing regimen for our anticipated Phase 3 trials,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “And most recently, we accomplished the goal of our previously scheduled preliminary injunction hearing as Valeant agreed not to launch efinaconazole, its topical product candidate for onychomycosis, if approved, until after our final arbitration hearing in September of this year.”

Key Stats (on next page)…

Revenue decreased 48.33% from $3.29 million in the previous quarter. EPS decreased to $-0.42 in the quarter versus EPS of $-0.36 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.41 to a loss $0.39. For the current year, the average estimate has moved up from a loss of $1.64 to a loss of $1.58 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]